Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Varicella Zoster Virus May Cause Giant Cell Arteritis

Lara C. Pullen, PhD  |  August 3, 2015

GENERIC_Science_Research_500x270Although scientists characterize giant cell arteritis (GCA) as an immune-mediated disease, its cause is unknown. A new study by Don Gilden, MD, and Maria Nagel, MD, of the University of Colorado School of Medicine in Aurora, Colo., suggests that an infection with the varicella zoster virus (VZV) may trigger GCA. The neurologists published their analysis of temporal arteries (TAs) in a supplement of the Journal of Infectious Diseases.1

VZV is a neurotropic virus found exclusively in humans. After causing chicken pox, the virus becomes latent in cranial nerve ganglia, dorsal root ganglia and autonomic ganglia along the entire neuroaxis. In elderly and immunocompromised individuals, VZV-specific, cell-mediated immunity declines and VZV reactivates from one or more ganglia. The reactivation results in a productive viral infection that can cause shingles. Shingles may also be complicated by VZV vasculopathy when the viral infection includes the cerebral arteries.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Originally, VZV vasculopathy was described as a large vessel stroke that resulted in hemiplegia after chicken pox or shingles. It can cause ischemic infarction of the brain and spinal cord, as well as subarachnoid and cerebral hemorrhage, aneurysm and carotid dissection. VZV vasculopathy can be unifocal or multifocal, with deep-seated and superficial infarctions. A diagnosis can be made by imaging lesions at the gray-white matter junction of the brain. Generally, both large and small arteries are involved, and most patients have mononuclear cerebrospinal fluid pleocytosis, often with red blood cells. In approximately one-third of the cases, however, cerebrospinal fluid pleocytosis and rash are absent. IgG antibody can be frequently detected in the cerebrospinal fluid, but VZV DNA is found less often.

Recently, the number of recognized vasculopathies has grown, making it somewhat difficult to diagnose and, therefore, treat these disorders effectively. Dr. Gilden and Dr. Nagel have recently expanded to the understanding that VZV vasculopathy includes transient ischemic attacks, ischemic and hemorrhagic stroke, and multifocal VZV vasculopathy. The VZV vasculopathy occurs in TAs and mimics GCA, extracranial vasculopathy, aneurysm with and without subarachnoid hemorrhage, and other disorders. All known cases of VZV vasculopathy have occurred in intracerebral arteries.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the current study, the investigators performed immunohistochemical analyses on formalin-fixed, paraffin-embedded sections from four GCA-positive TAs and 13 normal TAs. They employed antibodies from two different species that were directed against VZV. They found VZV antigen in all four GCA-positive TAs, but no antigen in normal TAs. The VZV was primarily located in the adventitia and media. There was less VZV in the intima.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsVasculitis Tagged with:Giant Cell Arteritisvaricella zoster virusVasculitisvasculopathy

Related Articles

    Research in Temporal Arteritis Suggests Link with Infection, Autoimmune Disease

    November 16, 2015

    Temporal arteritis was first described by Sir Jonathan Hutchinson in 1890 in an elderly retired gentleman’s servant who developed red, painful streaks on his temples and was found to have bilaterally swollen temporal arteries with feeble pulses.1 Sir Hutchinson disputed the suggestion that the red streaks were caused by the man’s hat and, instead, called…

    Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

    March 1, 2013

    Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

    Varicella Zoster Virus Not Associated with Giant Cell Arteritis Pathogenesis

    February 4, 2020

    Researchers suggest antiviral therapy is not appropriate for patients with GCA, based on their study findings and related research…

    Updates on Giant Cell Arteritis

    March 19, 2018

    SAN DIEGO—Recent research tells us more about giant cell arteritis (GCA) to help rheumatologists more accurately diagnose and effectively treat patients with this type of vasculitis. On Nov. 6 at the ACR/ARHP Annual Meeting, three experts explored the latest findings on GCA pathogenesis, diagnostic approaches, imaging modalities and growing treatment options. GCA: What’s Really Happening?…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences